Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Authors

Farshad Nassiri
Vikas Patil
Leeor S Yefet
Olivia Singh
Jeff Liu
Rachel M A Dang
Takafumi N Yamaguchi
Mariza Daras
Timothy F Cloughesy
Howard Colman
Priya U Kumthekar
Clark C Chen
Robert Aiken
Morris D Groves
Shirley S Ong
Rohan Ramakrishna
Michael A Vogelbaum
Simon Khagi
Thomas Kaley
Jason M Melear
David M Peereboom
Analiz Rodriguez
Maxim Yankelevich
Suresh G. Nair MD, Lehigh Valley Health NetworkFollow
Vinay K Puduvalli
Kenneth Aldape
Andrew Gao
Álvaro López-Janeiro
Carlos E de Andrea
Marta M Alonso
Paul Boutros
Joan Robbins
Warren P Mason
Adam M Sonabend
Roger Stupp
Juan Fueyo
Candelaria Gomez-Manzano
Frederick F Lang
Gelareh Zadeh

Publication/Presentation Date

7-21-2025

ISSN

1546-170X

Published In/Presented At

Nassiri, F., Patil, V., Yefet, L. S., Singh, O., Liu, J., Dang, R. M. A., Yamaguchi, T. N., Daras, M., Cloughesy, T. F., Colman, H., Kumthekar, P. U., Chen, C. C., Aiken, R., Groves, M. D., Ong, S. S., Ramakrishna, R., Vogelbaum, M. A., Khagi, S., Kaley, T., Melear, J. M., … Zadeh, G. (2025). Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nature medicine, 10.1038/s41591-025-03895-1. Advance online publication. https://doi.org/10.1038/s41591-025-03895-1

Disciplines

Medicine and Health Sciences

PubMedID

40691367

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute

Document Type

Article